JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mytilineou, C.
Right arrow Articles by Olanow, C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mytilineou, C.
Right arrow Articles by Olanow, C. W.

Vol. 284, Issue 2, 700-706, February 1998

Deprenyl and Desmethylselegiline Protect Mesencephalic Neurons from Toxicity Induced by Glutathione Depletion1

Catherine Mytilineou, Efthimia Kototos Leonardi, Pheona Radcliffe, Esa H. Heinonen, Shan-Kuo Han, Peter Werner, Gerald Cohen and C. Warren Olanow

Department of Neurology, Mount Sinai School of Medicine, New York, New York

Oxidative stress is thought to play an important role in the pathogenesis of Parkinson's disease (PD). Glutathione (GSH), a major cellular antioxidant, is decreased in the substantia nigra pars compacta of PD patients. The aim of the present study was to investigate whether deprenyl and its desmethyl metabolite, putative neuroprotective agents in the treatment of PD, could protect cultured rat mesencephalic neurons from cell death caused by GSH depletion due to treatment with L-buthionine-(S,R)-sulfoximine (BSO). BSO (10 µM) caused extensive cell death after 48 hr, as demonstrated by disruption of cellular integrity and release of lactate dehydrogenase into the culture medium. Both deprenyl and desmethylselegiline, at concentrations of 5 and 50 µM, significantly protected dopaminergic neurons from toxicity without preventing the BSO-induced loss in GSH. Protection was not associated with monoamine oxidase type B inhibition in that pargyline, a potent MAO inhibitor, was ineffective and pretreatment with pargyline did not prevent the protective effects of deprenyl. Protection was not associated with inhibition of dopamine uptake by deprenyl because the dopamine uptake inhibitor mazindol did not diminish BSO toxicity. The antioxidant ascorbic acid (200 µM) also protected against BSO-induced cell death, suggesting that oxidative events were involved. This study demonstrates that deprenyl and its desmethyl metabolite can diminish cell death associated with GSH depletion.


0022-3565/98/2842-0700$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
NeurologyHome page
C. W. Olanow
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease
Neurology, May 23, 2006; 66(10_suppl_4): S69 - S79.
[Abstract] [Full Text]


Home page
NeurologyHome page
P. Jenner
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease
Neurology, October 12, 2004; 63(7_suppl_2): S13 - S22.
[Full Text]


Home page
NeurologyHome page
C. W. Olanow, R. L. Watts, and W. C. Koller
An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment
Neurology, June 12, 2001; 56(suppl_5): S1 - S88.
[Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.